Perspective Therapeutics (CATX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.
Robert Burns has given his Buy rating due to a combination of factors related to the promising developments in Perspective Therapeutics’ clinical trials. The company recently dosed the first patient in a new cohort of a Phase 1/2a trial, which is assessing the safety of their targeted alpha-particle therapy, [212Pb]VMT01, in combination with Opdivo for treating melanoma. Preclinical studies have shown that this combination therapy has resulted in high response rates and significant tumor regression, particularly when used in conjunction with PD1 immunotherapy in models resistant to checkpoint inhibitors.
Furthermore, the research indicates that the effectiveness of [212Pb]VMT01 does not depend on fractionated dosing, unlike traditional radiation therapies. This suggests that a single dose can effectively work with immune checkpoint inhibitors to achieve complete tumor regression. Additionally, the presence of tumor-infiltrating lymphocytes (TILs) post-treatment has been noted, which are crucial for the success of immune checkpoint inhibitors. These promising results and mechanistic insights into the therapy’s action contribute to the positive outlook and Buy rating for Perspective Therapeutics’ stock.
In another report released on March 17, LifeSci Capital also maintained a Buy rating on the stock with a $21.00 price target.